Copyright Reports & Markets. All rights reserved.

Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019

Buy now

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Overview

              Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Development

                Products under Development by Stage of Development

                  Products under Development by Therapy Area

                    Products under Development by Indication

                      Products under Development by Companies

                        Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development

                                  Abeome Corp

                                    Ablynx NV

                                      Alligator Bioscience AB

                                        Apogenix AG

                                          Bristol-Myers Squibb Co

                                            Checkpoint Therapeutics Inc

                                              GigaGen Inc

                                                IGM Biosciences Inc

                                                  Incyte Corp

                                                    Leap Therapeutics Inc

                                                      Merck & Co Inc

                                                        Novartis AG

                                                          Regeneron Pharmaceuticals Inc

                                                            Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles

                                                              ABM-410 - Drug Profile

                                                                Product Description

                                                                  Mechanism Of Action

                                                                    R&D Progress

                                                                      ATOR-1144 - Drug Profile

                                                                        Product Description

                                                                          Mechanism Of Action

                                                                            R&D Progress

                                                                              BMS-986156 - Drug Profile

                                                                                Product Description

                                                                                  Mechanism Of Action

                                                                                    R&D Progress

                                                                                      CK-302 - Drug Profile

                                                                                        Product Description

                                                                                          Mechanism Of Action

                                                                                            R&D Progress

                                                                                              Fusion Protein to Agonize GITR for Solid Tumor and Hematological Tumor - Drug Profile

                                                                                                Product Description

                                                                                                  Mechanism Of Action

                                                                                                    R&D Progress

                                                                                                      GWN-323 - Drug Profile

                                                                                                        Product Description

                                                                                                          Mechanism Of Action

                                                                                                            R&D Progress

                                                                                                              INCAGN-1876 - Drug Profile

                                                                                                                Product Description

                                                                                                                  Mechanism Of Action

                                                                                                                    R&D Progress

                                                                                                                      MK-1248 - Drug Profile

                                                                                                                        Product Description

                                                                                                                          Mechanism Of Action

                                                                                                                            R&D Progress

                                                                                                                              MK-4166 - Drug Profile

                                                                                                                                Product Description

                                                                                                                                  Mechanism Of Action

                                                                                                                                    R&D Progress

                                                                                                                                      Monoclonal Antibodies to Agonize GITR for Oncology - Drug Profile

                                                                                                                                        Product Description

                                                                                                                                          Mechanism Of Action

                                                                                                                                            R&D Progress

                                                                                                                                              Monoclonal Antibodies to Agonize GITR for Oncology - Drug Profile

                                                                                                                                                Product Description

                                                                                                                                                  Mechanism Of Action

                                                                                                                                                    R&D Progress

                                                                                                                                                      Monoclonal Antibody to Agonize GITR for Hematological Tumor and Solid Tumor - Drug Profile

                                                                                                                                                        Product Description

                                                                                                                                                          Mechanism Of Action

                                                                                                                                                            R&D Progress

                                                                                                                                                              Monoclonal Antibody to Agonize GITR for Solid Tumors - Drug Profile

                                                                                                                                                                Product Description

                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                    R&D Progress

                                                                                                                                                                      PTZ-522 - Drug Profile

                                                                                                                                                                        Product Description

                                                                                                                                                                          Mechanism Of Action

                                                                                                                                                                            R&D Progress

                                                                                                                                                                              TRX-518 - Drug Profile

                                                                                                                                                                                Product Description

                                                                                                                                                                                  Mechanism Of Action

                                                                                                                                                                                    R&D Progress

                                                                                                                                                                                      Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Dormant Products

                                                                                                                                                                                        Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Discontinued Products

                                                                                                                                                                                          Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Product Development Milestones

                                                                                                                                                                                            Featured News & Press Releases

                                                                                                                                                                                              Jul 23, 2019: Excellent preclinical efficacy data of Apogenix' HERA-GITRL published in Journal for ImmunoTherapy of Cancer

                                                                                                                                                                                                Jun 04, 2019: GITR is an attractive target for immunotherapy

                                                                                                                                                                                                  May 07, 2019: Apogenix to present its Fusion Protein to Agonize GITR for Solid Tumor at upcoming International Conference

                                                                                                                                                                                                    Apr 02, 2019: Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects

                                                                                                                                                                                                      Dec 14, 2018: Leap therapeutics presents data on its oncology drug candidate TRX518 at ESMO Immuno-Oncology Congress 2018

                                                                                                                                                                                                        Oct 30, 2018: Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144

                                                                                                                                                                                                          Jan 16, 2018: Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial

                                                                                                                                                                                                            Nov 13, 2017: Leap Therapeutics Provides Update on its Antineoplastic Drug Candidate TRX-518

                                                                                                                                                                                                              Apr 03, 2017: Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 at the 2017 AACR Annual Meeting

                                                                                                                                                                                                                Mar 07, 2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting

                                                                                                                                                                                                                  Mar 01, 2017: Leap Therapeutics to Present Clinical Data on TRX518 at 2017 AACR Annual Meeting

                                                                                                                                                                                                                    Nov 12, 2016: Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist

                                                                                                                                                                                                                      Jun 22, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors

                                                                                                                                                                                                                        Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

                                                                                                                                                                                                                          Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting

                                                                                                                                                                                                                            Appendix

                                                                                                                                                                                                                              Methodology

                                                                                                                                                                                                                                Coverage

                                                                                                                                                                                                                                  Secondary Research

                                                                                                                                                                                                                                    Primary Research

                                                                                                                                                                                                                                      Expert Panel Validation

                                                                                                                                                                                                                                        Contact Us

                                                                                                                                                                                                                                          Disclaimer

                                                                                                                                                                                                                                          Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019

                                                                                                                                                                                                                                          Summary

                                                                                                                                                                                                                                          Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 15 molecules. The latest report Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

                                                                                                                                                                                                                                          Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Glucocorticoid induced tumor necrosis factor receptor or TNFRSF18 or AITR is a protein encoded by TNFRSF18 gene. TNFSF18 is involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. It mediated NF-kappa-B activation via the TRAF2/NIK pathway. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 5 and 3 respectively.

                                                                                                                                                                                                                                          Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Hematological Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Colorectal Tumor, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Fallopian Tube Cancer, Gastric Cancer, Hepatocellular Carcinoma, Lymphoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ocular Melanoma, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer and Renal Cell Carcinoma.

                                                                                                                                                                                                                                          Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

                                                                                                                                                                                                                                          Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                                                                          Scope

                                                                                                                                                                                                                                          - The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
                                                                                                                                                                                                                                          - The report reviews Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
                                                                                                                                                                                                                                          - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
                                                                                                                                                                                                                                          - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
                                                                                                                                                                                                                                          - The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects
                                                                                                                                                                                                                                          - The report assesses Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
                                                                                                                                                                                                                                          - The report summarizes all the dormant and discontinued pipeline projects
                                                                                                                                                                                                                                          - The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics

                                                                                                                                                                                                                                          Reasons to buy

                                                                                                                                                                                                                                          - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
                                                                                                                                                                                                                                          - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
                                                                                                                                                                                                                                          - Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
                                                                                                                                                                                                                                          - Identify the use of drugs for target identification and drug repurposing
                                                                                                                                                                                                                                          - Identify potential new clients or partners in the target demographic
                                                                                                                                                                                                                                          - Develop strategic initiatives by understanding the focus areas of leading companies
                                                                                                                                                                                                                                          - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
                                                                                                                                                                                                                                          - Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape
                                                                                                                                                                                                                                          - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

                                                                                                                                                                                                                                          Buy now